CJC-1295 Ipamorelin is the most extensively studied growth hormone secretagogue pairing in the peptide research literature — a GHRH analog and a selective ghrelin receptor agonist combined to produce dual-pathway pituitary activation that neither compound achieves alone. This pillar guide covers the receptor mechanisms, the published trial data, the comparison to exogenous HGH and alternative GH peptides, and the safety profile documented across the trial record.

For specific protocol design, reconstitution math, and DAC-vs-no-DAC dosing considerations, the CJC-1295 Ipamorelin dosage guide covers the practical side. For payment and sourcing at PSPeptides, the Affirm installment guide covers the checkout side. This article focuses on the underlying research.

The Two Peptides in the Stack

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — specifically a modified version of the first 29 amino acids of native GHRH (GRF 1-29, also called Sermorelin). The engineering replaces four amino acids to resist DPP-IV enzymatic cleavage, extending the compound’s stability substantially over its Sermorelin predecessor.

The compound exists in two research forms. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes and produces pulsatile GH release that mimics natural physiology. CJC-1295 with DAC binds serum albumin reversibly, extending the research half-life to 6–8 days and producing sustained rather than pulsatile GH elevation. The peptide half-life chart compares both forms against related GH-axis compounds.

Ipamorelin is a pentapeptide (five amino acids) that selectively activates the growth hormone secretagogue receptor (GHS-R1a) — the ghrelin receptor on anterior pituitary somatotrophs. Unlike earlier ghrelin mimetics such as GHRP-6 and GHRP-2, Ipamorelin does not meaningfully stimulate cortisol, prolactin, or appetite at research-relevant doses. This selectivity is the defining feature of the CJC-1295 Ipamorelin stack and the main reason researchers prefer it over earlier-generation GHRP combinations.

How Each Compound Works at the Receptor Level

Understanding the dual-pathway mechanism is essential for interpreting the trial data. Each peptide acts on a distinct GPCR population in the pituitary, and simultaneous activation produces synergistic effects that neither compound achieves alone.

CJC-1295 binds the GHRH receptor (GHRHR) on somatotroph cells. Activation triggers adenylyl cyclase, elevates intracellular cAMP, and activates protein kinase A. Downstream, GH gene transcription increases, new GH is synthesized, and the releasable pool of stored GH within somatotrophs expands. Functionally, CJC-1295 “loads the cannon” — it primes the pituitary with more GH available for release.

Ipamorelin acts through GHS-R1a via Gq signaling. Binding activates phospholipase C, produces IP3-mediated calcium release from intracellular stores, and triggers exocytosis of stored GH granules into circulation. Ipamorelin “pulls the trigger” on release. When both pathways activate simultaneously — through the combined stack — the pituitary produces GH pulses substantially larger than either compound produces individually.

CJC-1295 vs Ipamorelin: Distinct Roles in the Stack

The CJC-1295 vs Ipamorelin distinction matters because these compounds do fundamentally different things. Researchers occasionally ask which one is “better” — but the framing is wrong. CJC-1295 amplifies pulse amplitude by loading the somatotroph GH pool. Ipamorelin controls pulse frequency and timing through exocytosis. Used alone, each addresses only half of the somatotropic axis; used together, they engage both.

Published data suggests the combined stack can produce GH elevations 2–3× greater than either compound administered alone. The combination also preserves natural negative feedback through somatostatin — meaning GH cannot rise uncontrollably, a safety feature absent with exogenous HGH.

Published Research on the Combination

Several peer-reviewed studies characterize the two components of the CJC-1295 Ipamorelin stack. Most published trials investigate each peptide independently, but the mechanistic rationale for combination is well-supported.

The Ionescu & Frohman 2006 study published in the Journal of Clinical Endocrinology and Metabolism evaluated CJC-1295 with DAC in 66 healthy adult subjects. A single injection produced mean GH increases of 2–10 fold above baseline, with peak GH lasting 6 days. IGF-1 rose 1.5–3.0 fold above baseline and remained elevated for up to 28 days. The dose-response relationship was linear, with no serious adverse events across 56 days of observation.

Ipamorelin’s selectivity was characterized in the landmark Raun et al. 1998 preclinical study, which demonstrated dose-dependent GH release without measurable increases in cortisol (ACTH), prolactin, or FSH at doses up to 500 mcg/kg in animal models. This selectivity was attributed to unique binding characteristics at GHS-R1a that limit signal transduction to GH-producing pathways only.

A 2008 randomized, double-blind, placebo-controlled trial investigated Ipamorelin’s effects on postoperative ileus in 60 patients following major abdominal surgery. The Ipamorelin group demonstrated statistically significant improvements in GI motility recovery (p < 0.05) — suggesting GHS-R1a agonism has broader physiological relevance beyond simple GH secretion. Broader growth hormone peptide research has since expanded on this finding across recovery-related applications. PubMed indexes the primary Ipamorelin literature, the CJC-1295 GHRH research is separately catalogued, and NIH covers growth hormone physiology and regulation.

CJC-1295 Ipamorelin Benefits 2026: What the Current Research Landscape Shows

The CJC-1295 Ipamorelin benefits 2026 research picture is shaped by two developments: expanded selectivity data confirming Ipamorelin’s clean hormonal profile across larger sample sizes, and increased interest in dual-pathway secretagogues as alternatives to direct HGH administration. Growth hormone peptide research has broadly shifted toward endogenous stimulation models — where the pituitary retains feedback control — rather than exogenous replacement.

Current research applications span four main areas. Body composition research examines lipolysis and lean mass preservation without the supraphysiological GH levels associated with exogenous HGH. Sleep and recovery research leverages Ipamorelin’s cortisol-neutral profile to isolate GH effects on sleep architecture — see the peptides for sleep recovery guide for related peptide context. Longevity research examines whether restoring pulsatile GH patterns can offset the ~14% per decade decline in natural GH production after age 30 — the longevity peptide guide covers the broader landscape. Tissue repair research combines the stack with regenerative peptides like BPC-157 and TB-500.

Stack vs. Exogenous HGH: Why Researchers Choose Endogenous Stimulation

Comparison to Alternative GH Peptides

Versus Sermorelin

Sermorelin is the original GHRH(1-29) analog and the direct predecessor to CJC-1295. Both activate the same GHRHR, but CJC-1295 incorporates four amino acid substitutions that dramatically improve metabolic stability. Sermorelin has a research half-life of approximately 10–12 minutes due to rapid DPP-IV cleavage; CJC-1295 (no DAC) achieves ~30 minutes. That difference translates to more reproducible peak GH measurements in timed research protocols.

Versus GHRP-6 and GHRP-2

GHRP-6 and GHRP-2 were the first GHS-R agonists studied alongside GHRH analogs. Both produce robust GH release but lack Ipamorelin’s selectivity — GHRP-6 raises cortisol by approximately 52% and increases appetite significantly; GHRP-2 elevates prolactin. These off-target effects complicate experimental design and reduce interpretability of body composition and recovery data. Ipamorelin was specifically developed to address this limitation, which is why current growth hormone peptide research favors it over earlier GHRPs when a clean hormonal signal is required.

Versus MK-677 (Ibutamoren)

MK-677 is an orally bioavailable GHS-R agonist that shares Ipamorelin’s receptor target but differs in pharmacokinetics and selectivity. MK-677’s 24-hour half-life produces continuous GH and IGF-1 elevation rather than pulsatile release. Some researchers use this for sustained IGF-1 studies, but chronic activation increases appetite and can elevate cortisol and prolactin over time. Injection-based CJC-1295 Ipamorelin produces more physiological pulsatile GH patterns and avoids the GHS-R1a desensitization observed with continuous MK-677 administration. The MK-677 research guide covers the oral alternative in detail.

Safety Profile in the Published Research

The CJC-1295 Ipamorelin stack has documented a favorable tolerability profile across published trials. In the Ionescu & Frohman CJC-1295 phase 2 trial, the most commonly reported adverse events were transient injection site reactions (erythema, pain) in approximately 20% of subjects, and mild flushing sensations in 15%. Both were generally mild and self-limiting, resolving within 30–60 minutes. No serious adverse events attributable to CJC-1295 were reported across the 66 enrolled subjects over 56 days of observation.

Ipamorelin’s safety profile is characterized by its GH selectivity. Unlike GHRP-6 (which raises cortisol by up to 52% and ACTH by 61%), Ipamorelin produces no statistically significant changes in cortisol, prolactin, FSH, LH, or TSH at research-relevant doses. Water retention — common with exogenous GH — is minimal because the stack produces proportional, feedback-regulated IGF-1 elevation rather than sustained supraphysiological levels.

Researchers should note that GH peptides are inappropriate for subjects with active malignancy, and that elevated GH and IGF-1 may affect insulin sensitivity. Standard pre-research screening and monitoring protocols apply. The peptide side effects research guide covers adverse event data across the peptide class.

Protocol Design and Sourcing

Reconstitution, dosing, storage protocols, and DAC-vs-no-DAC selection are covered in depth in the CJC-1295 Ipamorelin dosage guide. Reconstitution procedure is covered in the peptide reconstitution guide, storage conditions in the peptide storage guide, and dilution math in the peptide calculator.

PSPeptides supplies both CJC-1295 and Ipamorelin at 99%+ HPLC-verified purity with batch-specific Certificates of Analysis. Mass spectrometry confirms molecular identity for each lot. The COA interpretation guide covers how to evaluate the documentation. Payment options — including Affirm installments for larger stack orders — are covered in the Affirm checkout guide and the peptide payment options overview.

Frequently Asked Questions

What’s the difference between CJC-1295 with DAC and without DAC?

CJC-1295 without DAC (Modified GRF 1-29) has a ~30-minute research half-life and produces pulsatile GH release mimicking natural physiology. CJC-1295 with DAC extends the half-life to 6–8 days through reversible serum albumin binding, creating sustained GH elevation. Most research protocols using the combination stack the non-DAC version for more physiological pulsatile GH patterns.

Can the stack be combined with tissue repair peptides?

Yes. Research protocols sometimes combine the GH secretagogue stack with tissue repair peptides like BPC-157, TB-500, and GHK-Cu. The theoretical basis is that elevated GH may enhance the healing cascade through increased protein synthesis and cellular regeneration.

Does Ipamorelin increase appetite like GHRP-6?

No. Ipamorelin is selective for GH release and does not significantly stimulate appetite, cortisol, or prolactin at research-relevant doses. This is one of its primary advantages over earlier GHS-R agonists like GHRP-6 and GHRP-2 that triggered multiple hormonal pathways simultaneously.

Is CJC-1295 the same as Sermorelin?

Related but not identical. Both are GHRH analogs based on the first 29 amino acids of GHRH. CJC-1295 has four amino acid substitutions that increase stability and resistance to DPP-IV enzyme degradation, giving it a longer duration of action. For research requiring more sustained GHRH pathway activation, CJC-1295 is generally preferred over Sermorelin.

How do growth hormone peptides compare to GLP-1 peptides?

They serve completely different research purposes. GH secretagogues stimulate growth hormone production for body composition, recovery, and anti-aging research. GLP-1 agonists like Retatrutide and semaglutide target metabolic pathways related to appetite suppression and glucose regulation.

What purity standards should researchers look for?

Research-grade CJC-1295 and Ipamorelin should be verified by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to confirm both purity and molecular identity. Published research typically requires ≥98% purity for controlled experiments. Researchers should always request and review the certificate of analysis (COA) for every batch.

All PSPeptides products are sold exclusively for research and laboratory use.